ReviewAntimicrobial agents and chemotherapy2015
Naegleria fowleri: pathogenesis, diagnosis, and treatment options.
Review in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 2 syntheses or guidelines pooled it, 241 citations in OpenAlex.
- Fatal brain infection in early life: primary amoebic meningoencephalitis caused by Naegleria fowleri in neonates and infants.BMC infectious diseases · 2026Pooled it
- Systematic Review of Brain-Eating Amoeba: A Decade Update.International journal of environmental research and public health · 2023Pooled it
- Cyclin-dependent kinase-inhibitor screening and structural analysis identify a CDK-like kinase candidate in Naegleria fowleri.Parasites & vectors · 2026Article
- Host factors, inflammatory markers, and clinical outcomes of Naegleria fowleri meningoencephalitis.Communications medicine · 2026Article
- Repurposing CNS drugs Zonisamide and Perampanel conjugated with silver nanoparticles as an anti-amoebic agent in combating Granulomatous Amebic Encephalitis (GAE) and Primary Amebic Meningoencephalitis (PAM) infection caused byParasite epidemiology and control · 2026Article
- Ginsenosides Rb3 and Rc Exhibit Anti-Amoebic Activities AgainstPharmaceuticals (Basel, Switzerland) · 2026Article
- Detection ofACS ES&T water · 2026Article
- Transgenic approaches in the pathogenic free-living amoebae: what are the hurdles?Parasitology · 2026Review
- Article
- Biological Activity of Stilbenoids Against Fungal, Parasitic, and Viral Pathogens.Molecules (Basel, Switzerland) · 2026Review
- Primary Amoebic Meningoencephalitis caused by Complement C2 Deficiency.medRxiv : the preprint server for health sciences · 2026Article
- In-silico Study of an Inhibitor of S-Adenosyl-L-Homocysteine Hydrolase (SAHH) of Naegleria fowleri using Molecular Docking, Density Functional Theory (DFT), and Molecular Dynamics (MD) Simulation.Molecular biotechnology · 2026Article
- Article
- The Activity of FDA-Approved Prodrug Isavuconazonium Sulfate and Its Major Metabolite Isavuconazole AgainstPharmaceutics · 2026Article
- Article
- Dynamics of an SEIDW epidemic model for primary amebic meningoencephalitis threshold analysis, bifurcation, and optimal environmental control.Frontiers in public health · 2026Article
- Development of dihydroquinazoline compounds as novel therapeutics against Naegleria fowleri.Bioorganic & medicinal chemistry letters · 2025Article
- Bibenzyl Derivatives fromMolecules (Basel, Switzerland) · 2025Article
- Potential Inhibitors of Human-Marine drugs · 2025Article
- Rare Naegleria fowleri meningoencephalitis diagnosed via combined molecular biology and metagenomic sequencing techniques: a case report.Infectious diseases of poverty · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naegleria fowleri has generated tremendous media attention over the last 5 years due to several high-profile cases. Several of these cases were followed very closely by the general public. N. fowleri is a eukaryotic, free-living amoeba belonging to the phylum Percolozoa. Naegleria amoebae are ubiquitous in the environment, being found in soil and bodies of freshwater, and feed on bacteria found in those locations. While N. fowleri infection appears to be quite rare compared to other diseases, the clinical manifestations of primary amoebic meningoencephalitis are devastating and nearly always fatal. Due to the rarity of N. fowleri infections in humans, there are no clinical trials to date that assess the efficacy of one treatment regimen over another. Most of the information regarding medication efficacy is based on either case reports or in vitro studies. This review will discuss the pathogenesis, diagnosis, pharmacotherapy, and prevention of N. fowleri infections in humans, including a brief review of all survivor cases in North America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.